Skip To Main Content
Lisa von Moltke on Muck Rack

Lisa von Moltke

As seen in: Nature, Infectious Diseases News
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Lisa von Moltke’s profile

Articles by Lisa von Moltke

A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial

|
By Doris M. Ponce, Zachariah DeFilipp, Christopher Ford, Mary-Jane Lombardo, David Lichter, Meghan E. Chafee, Satyajit Kosuri, Nandita Khera, Hemant S. Murthy, Karamjeet S. Sandhu, David N. Fredricks, Tessa M. Andermann, Rajneesh Nath, Kelly Brady, Brooke R. Hasson, Emily Walsh, Nathan D. Hicks, Jonathan Peled, Lisa von Moltke, Matthew R. Henn, Marcel R. M. van den Brink, Bina Tejura, Dennis M. Walling
| Nature Verified
Abstract Gastrointestinal (GI) microbiome disruption and impaired GI barrier integrity increase the risk of bloodstream infection (BSI) following allogeneic hematopoietic cell transplant.
Open in Who Shared Issue with article?

FDA-approved microbiome therapy reduces recurrent CDI, regardless of risk factors

|
By Caitlyn Stulpin Verified, Carol L. DiBerardino Verified, Lisa von Moltke
| Infectious Diseases News Verified
Source/Disclosures Source: Berenson CS, et al. Clin Infect Dis. 2023;doi:10.1093/cid/ciad448. Disclosures: Von Moltke is employed by Seres Therapeutics. Please see the study for all other authors’ relevant financial disclosures. You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Open in Who Shared Issue with article?
Show More